Actemra (tocilizumab subcutaneous injection) — Medica

Initial criteria

• age ≥ 18 years
• elevated acute phase reactants (CRP ≥ 6 mg/mL OR ESR ≥ 28 mm/h OR platelet count ≥ 330 x 10^9/L)
• forced vital capacity > 55% predicted value
• diagnosis confirmed by high-resolution computed tomography
• prescribed by or in consultation with a pulmonologist or rheumatologist

Reauthorization criteria

• age ≥ 18 years
• beneficial response to therapy over previous 1 year while receiving a tocilizumab product (e.g., reduction in decline in forced vital capacity, improvement in 6-minute walk distance, or reduction in disease-related exacerbations)
• prescribed by or in consultation with a pulmonologist or rheumatologist

Approval duration

1 year